Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.93 CAD | -1.17% | -2.31% | +14.26% |
Sales 2024 * | 346M 253M | Sales 2025 * | 356M 261M | Capitalization | 608M 446M |
---|---|---|---|---|---|
Net income 2024 * | 2M 1.47M | Net income 2025 * | 13M 9.53M | EV / Sales 2024 * | 1.76 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.71 x |
P/E ratio 2024 * |
210
x | P/E ratio 2025 * |
58.8
x | Employees | 725 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.64% |
Latest transcript on Knight Therapeutics Inc.
1 day | -3.00% | ||
1 week | -4.12% | ||
Current month | +0.87% | ||
1 month | +0.52% | ||
3 months | +4.86% | ||
6 months | +10.44% | ||
Current year | +12.14% |
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 13-10-31 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 16-06-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 14-01-05 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Robert Lande
BRD | Director/Board Member | 61 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.19% | 11 M€ | -.--% | ||
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 5.93 | -1.17% | 146 128 |
24-05-27 | 6 | 0.00% | 11,486 |
24-05-24 | 6 | +0.67% | 72,866 |
24-05-23 | 5.96 | -0.67% | 68,934 |
24-05-22 | 6 | -1.15% | 49,209 |
Delayed Quote Toronto S.E., May 28, 2024 at 10:21 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.14% | 446M | |
+16.17% | 79.03B | |
+8.65% | 8.78B | |
-16.73% | 4.83B | |
+48.34% | 4.65B | |
+2.03% | 3.89B | |
+18.57% | 2.34B | |
-26.94% | 2.18B | |
+16.55% | 2.11B | |
-36.25% | 2B |
- Stock Market
- Equities
- GUD Stock